

# Abington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	10	14.3	70.1	(33.6-128.9)	Male	8	8.0	99.6	(42.9-196.3)
Female	5	5.3	94.5	(30.5-220.6)	Female	10	6.7	148.4	(71.1-273.0)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.9	nc	(nc-nc)	Male	3	2.1	nc	(nc-nc)
Female	4	2.6	nc	(nc-nc)	Female	8	1.7	463.9	(199.8-914.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.5	nc	(nc-nc)	Male	11	7.6	144.2	(71.9-258.1)
Female	68	56.8	119.6	(92.9-151.7)	Female	2	7.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	2.6	nc	(nc-nc)	Male	5	5.7	87.3	(28.1-203.6)
<u>Colon / Rectum</u>					Female	2	2.8	nc	(nc-nc)
Male	18	21.9	82.4	(48.8-130.2)	<u>Ovary</u>				
Female	34	21.8	155.7	(107.8-217.6)	Female	7	6.0	116.9	(46.8-240.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	3.6	165.3	(60.3-359.7)	Male	1	4.1	nc	(nc-nc)
Female	1	1.0	nc	(nc-nc)	Female	3	4.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.3	nc	(nc-nc)	Male	49	58.5	83.7	(61.9-110.7)
Female	0	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	7	3.7	189.8	(76.0-391.0)
Male	8	6.1	130.7	(56.3-257.6)	Female	1	2.3	nc	(nc-nc)
Female	7	3.9	177.3	(71.0-365.2)	<u>Testis</u>				
<u>Larynx</u>					Male	4	2.3	nc	(nc-nc)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	1	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	9	5.6	161.0	(73.4-305.6)
Male	10	4.7	214.6	(102.7-394.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	4.0	nc	(nc-nc)	Female	15	11.4	131.5	(73.6-217.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.9	nc	(nc-nc)	Male	194	194.7	99.6	(86.1-114.7)
Female	1	1.1	nc	(nc-nc)	Female	238	188.3	126.4	(110.9-143.5)
<u>Lung and Bronchus</u>									
Male	36	27.2	132.5	(92.8-183.4)					
Female	34	25.2	134.7	(93.3-188.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	16.1	99.6	(56.9-161.8)	Male	11	10.3	107.0	(53.3-191.5)
Female	4	5.5	nc	(nc-nc)	Female	12	8.6	138.8	(71.6-242.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.9	nc	(nc-nc)	Male	1	2.5	nc	(nc-nc)
Female	0	3.2	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.6	nc	(nc-nc)	Male	11	9.4	116.6	(58.1-208.6)
Female	101	73.1	138.3	(112.6-168.0)	Female	13	7.9	165.1	(87.8-282.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	3.6	nc	(nc-nc)	Male	5	7.6	65.8	(21.2-153.6)
<u>Colon / Rectum</u>					Female	5	3.4	148.8	(48.0-347.3)
Male	25	25.4	98.4	(63.7-145.3)	<u>Ovary</u>				
Female	18	22.6	79.7	(47.2-126.0)	Female	5	7.4	67.3	(21.7-156.9)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	4.4	nc	(nc-nc)	Male	7	4.8	144.6	(57.9-298.0)
Female	1	1.1	nc	(nc-nc)	Female	4	4.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	1.7	nc	(nc-nc)	Male	69	71.4	96.7	(75.2-122.4)
Female	2	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	4.2	nc	(nc-nc)
Male	6	7.8	76.9	(28.1-167.4)	Female	1	2.3	nc	(nc-nc)
Female	5	4.6	108.3	(34.9-252.7)	<u>Testis</u>				
<u>Larynx</u>					Male	3	3.2	nc	(nc-nc)
Male	2	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	5	2.3	213.1	(68.7-497.3)
<u>Leukemia</u>					Female	6	7.9	76.4	(27.9-166.3)
Male	5	5.7	88.3	(28.5-206.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.5	nc	(nc-nc)	Female	16	14.6	109.8	(62.7-178.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	3.7	nc	(nc-nc)	Male	200	235.3	85.0	(73.6-97.6)
Female	1	1.2	nc	(nc-nc)	Female	235	223.0	105.4	(92.3-119.7)
<u>Lung and Bronchus</u>									
Male	14	31.9	43.8	(24.0-73.6)					
Female	23	27.8	82.8	(52.5-124.2)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Acushnet

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	12.4	88.7	(44.2-158.7)	Male	7	6.6	105.9	(42.4-218.1)
Female	3	4.2	nc	(nc-nc)	Female	3	5.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	2.3	262.9	(96.0-572.2)	Male	3	1.8	nc	(nc-nc)
Female	2	1.9	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	4	6.3	nc	(nc-nc)
Female	46	44.8	102.7	(75.2-137.0)	Female	2	5.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	1.9	nc	(nc-nc)	Male	3	4.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.2	nc	(nc-nc)
Male	24	18.8	127.7	(81.8-189.9)	<u>Ovary</u>				
Female	18	16.9	106.4	(63.0-168.2)	Female	3	4.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.1	nc	(nc-nc)	Male	9	3.6	252.9	(115.4-480.1)
Female	0	0.8	nc	(nc-nc)	Female	2	3.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.9	nc	(nc-nc)	Male	46	51.0	90.1	(66.0-120.2)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	3.1	nc	(nc-nc)
Male	9	5.2	173.9	(79.3-330.1)	Female	3	1.7	nc	(nc-nc)
Female	5	3.2	158.5	(51.1-369.9)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.0	nc	(nc-nc)
Male	4	3.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	3.0	nc	(nc-nc)	Female	5	9.2	54.5	(17.6-127.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.4	nc	(nc-nc)	Male	182	166.4	109.4	(94.1-126.5)
Female	2	0.8	nc	(nc-nc)	Female	130	147.6	88.1	(73.6-104.6)
<u>Lung and Bronchus</u>									
Male	29	23.9	121.4	(81.3-174.3)					
Female	21	20.7	101.6	(62.9-155.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Adams

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	15	12.7	118.4	(66.2-195.3)	Male	2	6.1	nc	(nc-nc)
Female	0	4.9	nc	(nc-nc)	Female	2	5.0	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	2.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	2	2.0	nc	(nc-nc)	Female	2	1.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	6.0	132.9	(57.2-262.0)
Female	40	44.8	89.3	(63.8-121.6)	Female	4	6.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.8	nc	(nc-nc)	Male	4	4.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	2.4	nc	(nc-nc)
Male	22	18.8	116.9	(73.2-177.0)	<u>Ovary</u>				
Female	26	20.7	125.9	(82.2-184.5)	Female	5	4.9	103.0	(33.2-240.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	3.0	167.2	(53.9-390.2)	Male	5	3.5	141.1	(45.5-329.3)
Female	1	1.0	nc	(nc-nc)	Female	3	4.4	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.8	nc	(nc-nc)	Male	51	48.3	105.6	(78.6-138.9)
Female	0	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	3.2	nc	(nc-nc)
Male	12	4.8	248.3	(128.1-433.8)	Female	1	2.2	nc	(nc-nc)
Female	4	3.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.2	nc	(nc-nc)
Male	6	2.1	291.4	(106.4-634.4)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Leukemia</u>					Female	3	3.5	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.4	nc	(nc-nc)	Female	8	9.1	87.8	(37.8-173.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	2.2	nc	(nc-nc)	Male	170	160.7	105.8	(90.5-123.0)
Female	1	1.0	nc	(nc-nc)	Female	149	158.8	93.8	(79.4-110.2)
<u>Lung and Bronchus</u>									
Male	23	23.6	97.3	(61.7-146.0)					
Female	27	23.0	117.5	(77.4-171.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Agawam

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	38	33.7	112.8	(79.8-154.9)	Male	14	17.7	79.2	(43.3-132.9)
Female	12	13.6	88.0	(45.4-153.7)	Female	14	15.1	92.7	(50.6-155.5)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	2	6.1	nc	(nc-nc)	Male	2	4.9	nc	(nc-nc)
Female	6	5.8	103.9	(37.9-226.1)	Female	2	4.4	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	1.0	nc	(nc-nc)	Male	18	17.0	105.8	(62.6-167.2)
Female	126	132.5	95.1	(79.2-113.2)	Female	21	17.3	121.6	(75.2-185.8)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	2	5.6	nc	(nc-nc)	Male	12	12.5	96.1	(49.6-167.9)
<b><u>Colon / Rectum</u></b>					Female	3	6.8	nc	(nc-nc)
Male	47	51.0	92.2	(67.8-122.7)	<b><u>Ovary</u></b>				
Female	58	57.3	101.1	(76.8-130.8)	Female	16	14.2	112.7	(64.4-183.0)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	2	8.2	nc	(nc-nc)	Male	4	9.6	nc	(nc-nc)
Female	4	2.7	nc	(nc-nc)	Female	13	12.1	107.7	(57.3-184.2)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.5	nc	(nc-nc)	Male	118	131.6	89.6	(74.2-107.3)
Female	4	2.2	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	7	8.6	81.2	(32.5-167.4)
Male	17	13.6	125.0	(72.8-200.1)	Female	6	6.2	97.2	(35.5-211.5)
Female	11	9.6	115.1	(57.4-206.0)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	2	4.3	nc	(nc-nc)
Male	4	5.7	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	1	1.7	nc	(nc-nc)	Male	4	3.4	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	11	11.4	96.6	(48.1-172.8)
Male	8	10.3	77.5	(33.3-152.6)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	9.7	103.4	(49.5-190.1)	Female	25	26.7	93.6	(60.6-138.2)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	5	6.3	78.8	(25.4-184.0)	Male	412	441.3	93.4	(84.6-102.8)
Female	1	2.7	nc	(nc-nc)	Female	428	455.7	93.9	(85.2-103.3)
<b><u>Lung and Bronchus</u></b>									
Male	72	63.1	114.1	(89.3-143.7)					
Female	57	62.7	91.0	(68.9-117.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Alford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	0	0.8	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	4	2.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.1	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Ovary</u>				
Female	1	0.8	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.0	nc	(nc-nc)	Male	4	3.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.2	nc	(nc-nc)
Male	0	0.3	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.1	nc	(nc-nc)	Male	11	9.9	111.4	(55.5-199.4)
Female	0	0.0	nc	(nc-nc)	Female	9	6.8	132.6	(60.5-251.7)
<u>Lung and Bronchus</u>									
Male	1	1.4	nc	(nc-nc)					
Female	1	0.9	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amesbury

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	14	14.8	94.7	(51.8-159.0)	Male	7	8.6	81.9	(32.8-168.7)
Female	6	5.8	103.8	(37.9-226.0)	Female	11	7.5	146.7	(73.1-262.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.1	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	2.8	nc	(nc-nc)	Female	6	1.9	318.6	(116.3-693.5)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.5	nc	(nc-nc)	Male	7	8.0	87.0	(34.9-179.3)
Female	54	62.4	86.5	(65.0-112.9)	Female	8	7.7	104.4	(44.9-205.7)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	3.0	nc	(nc-nc)	Male	8	6.0	134.0	(57.7-264.1)
<u>Colon / Rectum</u>					Female	5	3.1	162.1	(52.2-378.2)
Male	19	22.7	83.9	(50.5-131.0)	<u>Ovary</u>				
Female	24	23.9	100.5	(64.4-149.5)	Female	3	6.6	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	3.8	239.2	(109.1-454.0)	Male	3	4.3	nc	(nc-nc)
Female	1	1.1	nc	(nc-nc)	Female	6	5.0	119.6	(43.7-260.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	71	60.5	117.4	(91.7-148.1)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	3.8	nc	(nc-nc)
Male	13	6.4	202.2	(107.6-345.8)	Female	2	2.6	nc	(nc-nc)
Female	6	4.3	139.5	(50.9-303.6)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.7	188.6	(60.8-440.1)
Male	1	2.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	3	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.3	nc	(nc-nc)
Male	6	4.9	122.3	(44.7-266.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	4.4	114.1	(36.8-266.3)	Female	15	12.3	121.6	(68.0-200.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	3.0	nc	(nc-nc)	Male	216	203.0	106.4	(92.7-121.6)
Female	2	1.2	nc	(nc-nc)	Female	209	206.3	101.3	(88.0-116.0)
<u>Lung and Bronchus</u>									
Male	27	28.3	95.4	(62.8-138.8)					
Female	32	27.3	117.3	(80.2-165.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Amherst

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	17.7	39.5	(15.8-81.4)	Male	8	11.0	72.7	(31.3-143.2)
Female	4	7.0	nc	(nc-nc)	Female	11	10.8	101.8	(50.7-182.1)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.7	nc	(nc-nc)	Male	3	2.6	nc	(nc-nc)
Female	2	4.2	nc	(nc-nc)	Female	5	2.3	217.9	(70.2-508.6)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.6	nc	(nc-nc)	Male	11	10.9	100.9	(50.3-180.6)
Female	82	77.4	105.9	(84.2-131.4)	Female	11	10.1	109.2	(54.5-195.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	3.9	nc	(nc-nc)	Male	4	7.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	4	4.1	nc	(nc-nc)
Male	23	27.3	84.3	(53.4-126.5)	<u>Ovary</u>				
Female	16	29.3	54.5	(31.2-88.6)	Female	9	8.7	102.9	(47.0-195.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	4.5	111.8	(36.0-260.9)	Male	6	5.1	116.9	(42.7-254.4)
Female	0	1.4	nc	(nc-nc)	Female	2	6.1	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.8	nc	(nc-nc)	Male	86	71.7	119.9	(95.9-148.1)
Female	3	3.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	4.7	107.4	(34.6-250.6)
Male	4	7.6	nc	(nc-nc)	Female	1	3.1	nc	(nc-nc)
Female	2	5.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	6.3	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.9	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
<u>Leukemia</u>					Female	4	10.3	nc	(nc-nc)
Male	8	6.8	117.3	(50.5-231.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	6.0	nc	(nc-nc)	Female	19	15.5	122.2	(73.5-190.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.6	nc	(nc-nc)	Male	209	253.4	82.5	(71.7-94.4)
Female	1	1.5	nc	(nc-nc)	Female	216	265.2	81.5	(71.0-93.1)
<u>Lung and Bronchus</u>									
Male	14	33.6	41.7	(22.8-70.0)					
Female	14	33.4	41.9	(22.9-70.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Andover

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	35	31.0	112.9	(78.6-157.0)	Male	12	17.7	67.6	(34.9-118.1)
Female	10	11.6	86.0	(41.2-158.2)	Female	18	14.9	120.7	(71.5-190.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	6.4	nc	(nc-nc)	Male	5	4.6	107.7	(34.7-251.3)
Female	5	5.7	87.7	(28.3-204.7)	Female	3	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.0	nc	(nc-nc)	Male	17	16.7	101.9	(59.3-163.2)
Female	146	131.0	111.4	(94.1-131.0)	Female	22	15.4	142.5	(89.3-215.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	5.9	nc	(nc-nc)	Male	12	13.1	91.4	(47.2-159.6)
<u>Colon / Rectum</u>					Female	7	6.3	110.6	(44.3-227.9)
Male	40	48.0	83.4	(59.5-113.5)	<u>Ovary</u>				
Female	43	48.0	89.5	(64.8-120.6)	Female	7	13.6	51.4	(20.6-105.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	8.1	61.5	(19.8-143.5)	Male	15	9.1	164.3	(91.9-270.9)
Female	3	2.3	nc	(nc-nc)	Female	9	10.0	89.6	(40.9-170.1)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	2.6	nc	(nc-nc)	Male	160	132.1	121.2	(103.1-141.4)
Female	3	2.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	6	8.0	74.8	(27.3-162.7)
Male	12	13.8	86.8	(44.8-151.6)	Female	3	5.1	nc	(nc-nc)
Female	8	8.8	90.5	(39.0-178.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	4.3	nc	(nc-nc)
Male	2	5.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
<u>Leukemia</u>					Female	19	12.2	155.1	(93.4-242.3)
Male	10	10.1	99.0	(47.4-182.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	8.7	80.5	(32.2-165.8)	Female	20	26.4	75.9	(46.3-117.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.5	nc	(nc-nc)	Male	414	431.4	96.0	(86.9-105.7)
Female	1	2.4	nc	(nc-nc)	Female	398	422.5	94.2	(85.2-103.9)
<u>Lung and Bronchus</u>									
Male	43	60.3	71.3	(51.6-96.0)					
Female	39	55.8	69.9	(49.7-95.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Aquinnah

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.1	nc	(nc-nc)
Male	1	0.5	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	0	0.5	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	0	0.1	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	2	1.3	nc	(nc-nc)
Female	0	0.0	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	0	0.1	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	Female	0	0.0	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.0	nc	(nc-nc)
Male	0	0.1	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.0	nc	(nc-nc)	Male	0	0.0	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.1	nc	(nc-nc)
Male	2	0.1	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	0	0.1	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	1	0.1	nc	(nc-nc)	Male	8	4.2	190.3	(82.0-375.1)
Female	0	0.0	nc	(nc-nc)	Female	0	4.0	nc	(nc-nc)
<b><u>Lung and Bronchus</u></b>									
Male	0	0.6	nc	(nc-nc)					
Female	0	0.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Arlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	44	49.2	89.5	(65.0-120.2)	Male	30	25.9	115.9	(78.2-165.4)
Female	20	20.8	96.1	(58.7-148.5)	Female	21	23.8	88.2	(54.6-134.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	8.8	113.2	(54.2-208.2)	Male	9	7.1	127.4	(58.1-241.8)
Female	8	8.9	90.2	(38.8-177.8)	Female	10	6.8	147.4	(70.6-271.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	1.5	nc	(nc-nc)	Male	27	24.8	108.8	(71.7-158.2)
Female	191	203.6	93.8	(81.0-108.1)	Female	27	26.6	101.6	(67.0-147.9)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	6	8.9	67.5	(24.6-146.9)	Male	21	17.8	117.9	(73.0-180.2)
<u>Colon / Rectum</u>					Female	9	10.4	86.4	(39.4-164.1)
Male	61	73.9	82.5	(63.1-106.0)	<u>Ovary</u>				
Female	79	86.4	91.5	(72.4-114.0)	Female	17	21.7	78.2	(45.5-125.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	12.0	58.4	(23.4-120.4)	Male	6	13.9	43.2	(15.8-94.0)
Female	5	4.1	121.5	(39.2-283.6)	Female	18	18.3	98.4	(58.3-155.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	3.8	nc	(nc-nc)	Male	191	194.2	98.3	(84.9-113.3)
Female	4	3.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	8	12.5	64.1	(27.6-126.3)
Male	22	19.7	111.4	(69.8-168.7)	Female	5	9.2	54.3	(17.5-126.7)
Female	16	14.7	108.5	(62.0-176.3)	<u>Testis</u>				
<u>Larynx</u>					Male	4	7.1	nc	(nc-nc)
Male	9	8.3	108.3	(49.4-205.6)	<u>Thyroid</u>				
Female	5	2.6	192.4	(62.0-449.1)	Male	8	5.2	155.2	(66.8-305.7)
<u>Leukemia</u>					Female	29	18.4	157.2	(105.3-225.8)
Male	15	15.0	99.8	(55.8-164.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	15	14.7	101.9	(57.0-168.1)	Female	40	41.0	97.6	(69.7-133.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	9	9.2	97.9	(44.7-185.8)	Male	590	646.3	91.3	(84.1-99.0)
Female	6	4.2	144.5	(52.8-314.5)	Female	670	699.2	95.8	(88.7-103.4)
<u>Lung and Bronchus</u>									
Male	64	92.8	69.0	(53.1-88.1)					
Female	87	97.3	89.4	(71.6-110.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashburnham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	4.6	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	Female	2	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	1.1	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	2.7	nc	(nc-nc)
Female	18	19.1	94.4	(55.9-149.2)	Female	4	2.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.0	nc	(nc-nc)	Male	1	2.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.9	nc	(nc-nc)
Male	10	7.3	136.7	(65.5-251.5)	<u>Ovary</u>				
Female	11	6.0	183.3	(91.4-328.0)	Female	2	1.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	1.3	397.1	(128.0-926.6)	Male	4	1.4	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	4	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	15	20.2	74.3	(41.5-122.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	1.2	nc	(nc-nc)
Male	4	2.2	nc	(nc-nc)	Female	1	0.6	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.9	nc	(nc-nc)
Male	1	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
<u>Leukemia</u>					Female	0	2.1	nc	(nc-nc)
Male	3	1.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.2	nc	(nc-nc)	Female	2	3.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	65	67.2	96.7	(74.7-123.3)
Female	2	0.3	nc	(nc-nc)	Female	68	58.7	115.8	(89.9-146.8)
<u>Lung and Bronchus</u>									
Male	7	9.2	76.0	(30.5-156.7)					
Female	6	7.4	80.7	(29.5-175.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashby

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.4	nc	(nc-nc)	Male	0	1.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.6	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.4	nc	(nc-nc)
Female	9	10.0	89.9	(41.0-170.6)	Female	0	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.5	nc	(nc-nc)	Male	2	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.5	nc	(nc-nc)
Male	4	3.7	nc	(nc-nc)	<u>Ovary</u>				
Female	6	3.4	178.7	(65.2-388.9)	Female	0	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	10.5	113.9	(58.8-199.0)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	2	1.1	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.1	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	0.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.5	nc	(nc-nc)	Male	35	34.7	101.0	(70.3-140.5)
Female	0	0.2	nc	(nc-nc)	Female	36	31.5	114.3	(80.0-158.2)
<u>Lung and Bronchus</u>									
Male	5	4.8	104.6	(33.7-244.1)					
Female	6	4.1	147.3	(53.8-320.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.0	nc	(nc-nc)	Male	3	1.1	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	1	0.3	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
Female	8	7.8	102.8	(44.2-202.5)	Female	0	0.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	3.1	nc	(nc-nc)	<u>Ovary</u>				
Female	3	2.5	nc	(nc-nc)	Female	2	0.8	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.5	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	12	8.1	147.8	(76.3-258.2)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.5	nc	(nc-nc)
Male	2	0.9	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	30	27.3	110.0	(74.2-157.1)
Female	0	0.1	nc	(nc-nc)	Female	22	23.9	92.0	(57.6-139.3)
<u>Lung and Bronchus</u>									
Male	4	3.8	nc	(nc-nc)					
Female	2	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ashland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	18	12.5	144.5	(85.6-228.3)	Male	13	7.6	170.8	(90.8-292.0)
Female	3	4.3	nc	(nc-nc)	Female	6	6.5	92.0	(33.6-200.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.8	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	2	1.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	8	7.1	113.4	(48.8-223.4)
Female	48	53.8	89.2	(65.8-118.3)	Female	7	6.0	116.4	(46.6-239.7)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	2.7	nc	(nc-nc)	Male	6	5.4	110.6	(40.4-240.8)
<u>Colon / Rectum</u>					Female	0	2.5	nc	(nc-nc)
Male	25	19.4	128.9	(83.4-190.4)	<u>Ovary</u>				
Female	23	17.1	134.6	(85.3-202.0)	Female	6	5.5	109.0	(39.8-237.3)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	4	3.3	nc	(nc-nc)	Male	4	3.7	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	7	3.6	195.1	(78.2-402.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	45	53.5	84.1	(61.4-112.6)
Female	3	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	3.2	nc	(nc-nc)
Male	3	5.8	nc	(nc-nc)	Female	0	1.7	nc	(nc-nc)
Female	2	3.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.4	nc	(nc-nc)
Male	2	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	0.6	nc	(nc-nc)	Male	0	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.9	84.8	(27.3-198.0)
Male	4	4.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	3.4	nc	(nc-nc)	Female	11	10.8	102.2	(51.0-182.9)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.7	nc	(nc-nc)	Male	156	177.4	87.9	(74.7-102.9)
Female	0	0.9	nc	(nc-nc)	Female	161	167.5	96.1	(81.9-112.2)
<u>Lung and Bronchus</u>									
Male	10	24.5	40.7	(19.5-74.9)					
Female	22	21.7	101.6	(63.7-153.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Athol

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	14.0	93.1	(49.5-159.2)	Male	6	7.0	85.6	(31.3-186.4)
Female	2	5.4	nc	(nc-nc)	Female	3	5.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	2.0	nc	(nc-nc)
Female	1	2.2	nc	(nc-nc)	Female	1	1.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.4	nc	(nc-nc)	Male	6	6.9	87.6	(32.0-190.6)
Female	40	49.8	80.3	(57.4-109.3)	Female	7	6.7	104.0	(41.7-214.4)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	2.1	nc	(nc-nc)	Male	4	4.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	28	20.9	134.3	(89.2-194.0)	<u>Ovary</u>				
Female	14	22.5	62.1	(33.9-104.3)	Female	4	5.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	3.3	nc	(nc-nc)	Male	2	3.9	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	Female	8	4.8	168.1	(72.4-331.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.0	nc	(nc-nc)	Male	50	52.3	95.6	(71.0-126.1)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	3.6	140.3	(45.2-327.4)
Male	4	5.4	nc	(nc-nc)	Female	1	2.4	nc	(nc-nc)
Female	2	3.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.6	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.6	nc	(nc-nc)	Male	5	1.3	381.4	(122.9-890.1)
<u>Leukemia</u>					Female	1	4.2	nc	(nc-nc)
Male	6	4.2	141.6	(51.7-308.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.8	131.5	(42.4-307.0)	Female	9	10.0	90.4	(41.2-171.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	2.5	nc	(nc-nc)	Male	187	177.7	105.2	(90.7-121.4)
Female	2	1.1	nc	(nc-nc)	Female	136	174.9	77.7	(65.2-92.0)
<u>Lung and Bronchus</u>									
Male	31	25.6	121.1	(82.3-171.9)					
Female	17	24.5	69.5	(40.5-111.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Attleboro

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	30	39.7	75.5	(50.9-107.8)	Male	21	22.3	94.2	(58.3-143.9)
Female	19	15.8	120.5	(72.5-188.2)	Female	24	19.4	123.9	(79.3-184.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	8.1	159.7	(85.0-273.1)	Male	5	5.8	86.0	(27.7-200.6)
Female	9	7.4	121.2	(55.3-230.0)	Female	5	5.1	97.6	(31.4-227.7)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.3	nc	(nc-nc)	Male	17	21.2	80.2	(46.7-128.4)
Female	154	162.0	95.0	(80.6-111.3)	Female	17	20.6	82.4	(48.0-131.9)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	7.5	nc	(nc-nc)	Male	18	15.5	116.1	(68.8-183.5)
<u>Colon / Rectum</u>					Female	12	8.2	147.0	(75.9-256.9)
Male	43	60.5	71.0	(51.4-95.7)	<u>Ovary</u>				
Female	56	65.2	85.8	(64.8-111.5)	Female	17	17.2	98.7	(57.5-158.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	15	10.0	150.1	(84.0-247.6)	Male	5	11.4	43.7	(14.1-102.0)
Female	2	3.1	nc	(nc-nc)	Female	14	13.8	101.8	(55.6-170.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.7	136.9	(44.1-319.5)	Male	156	161.8	96.4	(81.9-112.8)
Female	2	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	12	10.2	117.8	(60.8-205.7)
Male	20	16.9	118.3	(72.2-182.6)	Female	5	6.9	72.0	(23.2-167.9)
Female	11	11.5	95.6	(47.7-171.1)	<u>Testis</u>				
<u>Larynx</u>					Male	7	6.9	101.2	(40.5-208.5)
Male	5	7.0	71.3	(23.0-166.3)	<u>Thyroid</u>				
Female	2	2.0	nc	(nc-nc)	Male	7	4.7	147.8	(59.2-304.5)
<u>Leukemia</u>					Female	19	15.9	119.6	(72.0-186.8)
Male	9	13.0	69.2	(31.6-131.3)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	11.7	102.3	(52.8-178.6)	Female	29	32.5	89.3	(59.8-128.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	10	7.8	127.5	(61.0-234.5)	Male	529	540.4	97.9	(89.7-106.6)
Female	3	3.2	nc	(nc-nc)	Female	519	547.7	94.8	(86.8-103.3)
<u>Lung and Bronchus</u>									
Male	85	76.1	111.7	(89.2-138.1)					
Female	74	74.2	99.7	(78.3-125.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Auburn

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	24	21.5	111.7	(71.5-166.2)	Male	5	10.8	46.4	(15.0-108.3)
Female	11	7.9	140.1	(69.8-250.7)	Female	3	8.6	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	3.6	nc	(nc-nc)	Male	5	3.1	162.7	(52.4-379.7)
Female	4	3.3	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.7	nc	(nc-nc)	Male	10	10.5	95.5	(45.7-175.7)
Female	60	76.6	78.3	(59.7-100.8)	Female	9	10.0	90.4	(41.3-171.7)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	3.2	nc	(nc-nc)	Male	7	7.6	92.5	(37.0-190.5)
<u>Colon / Rectum</u>					Female	6	3.9	153.3	(56.0-333.7)
Male	29	32.2	90.1	(60.3-129.4)	<u>Ovary</u>				
Female	23	32.4	70.9	(44.9-106.4)	Female	6	8.2	73.4	(26.8-159.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	5.2	135.0	(54.1-278.3)	Male	5	6.1	82.3	(26.5-192.1)
Female	1	1.5	nc	(nc-nc)	Female	8	6.9	116.2	(50.0-228.9)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.4	nc	(nc-nc)	Male	73	83.9	87.0	(68.2-109.4)
Female	0	1.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	5.4	nc	(nc-nc)
Male	2	8.4	nc	(nc-nc)	Female	3	3.4	nc	(nc-nc)
Female	8	5.6	143.1	(61.6-281.9)	<u>Testis</u>				
<u>Larynx</u>					Male	5	2.3	215.2	(69.4-502.2)
Male	2	3.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.0	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Leukemia</u>					Female	4	6.4	nc	(nc-nc)
Male	2	6.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.5	109.2	(39.9-237.6)	Female	21	15.6	134.2	(83.1-205.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	5	3.9	128.2	(41.3-299.1)	Male	237	277.6	85.4	(74.8-97.0)
Female	0	1.6	nc	(nc-nc)	Female	240	262.4	91.5	(80.3-103.8)
<u>Lung and Bronchus</u>									
Male	32	40.4	79.3	(54.2-111.9)					
Female	47	37.1	126.7	(93.1-168.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Avon

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	7	5.7	123.2	(49.4-253.9)	Male	2	2.9	nc	(nc-nc)
Female	2	2.1	nc	(nc-nc)	Female	2	2.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.0	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	18	20.9	86.3	(51.1-136.4)	Female	3	2.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	0.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	1.1	nc	(nc-nc)
Male	9	8.5	105.8	(48.3-200.8)	<u>Ovary</u>				
Female	13	8.2	158.3	(84.2-270.6)	Female	1	2.2	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.4	nc	(nc-nc)	Male	2	1.6	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	25	23.0	108.7	(70.3-160.4)
Female	1	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	1.4	nc	(nc-nc)
Male	1	2.3	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
Female	3	1.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.8	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	2	4.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.1	nc	(nc-nc)	Male	79	74.7	105.7	(83.7-131.7)
Female	0	0.4	nc	(nc-nc)	Female	85	70.2	121.1	(96.7-149.8)
<u>Lung and Bronchus</u>									
Male	10	10.8	92.2	(44.1-169.5)					
Female	19	10.2	186.7	(112.4-291.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Ayer

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	5.9	101.9	(37.2-221.9)	Male	1	3.5	nc	(nc-nc)
Female	3	2.5	nc	(nc-nc)	Female	2	3.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	1.3	nc	(nc-nc)	Male	2	0.9	nc	(nc-nc)
Female	0	1.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	1	3.3	nc	(nc-nc)
Female	24	25.2	95.2	(61.0-141.6)	Female	4	3.3	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.2	nc	(nc-nc)	Male	3	2.4	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.3	nc	(nc-nc)
Male	10	9.0	111.0	(53.1-204.1)	<u>Ovary</u>				
Female	6	10.4	57.8	(21.1-125.8)	Female	7	2.7	258.9	(103.7-533.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	1.5	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
Female	1	0.5	nc	(nc-nc)	Female	3	2.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.6	nc	(nc-nc)	Male	21	24.0	87.6	(54.2-133.9)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.5	nc	(nc-nc)
Male	5	2.6	195.4	(63.0-455.9)	Female	0	1.1	nc	(nc-nc)
Female	1	1.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.3	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.6	nc	(nc-nc)
Male	4	2.0	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	4	1.9	nc	(nc-nc)	Female	5	5.0	100.4	(32.4-234.3)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.2	nc	(nc-nc)	Male	75	81.3	92.2	(72.5-115.6)
Female	1	0.5	nc	(nc-nc)	Female	95	86.2	110.1	(89.1-134.7)
<u>Lung and Bronchus</u>									
Male	10	11.3	88.1	(42.2-162.1)					
Female	21	11.5	182.0	(112.6-278.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Barnstable

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	84	73.3	114.5	(91.4-141.8)	Male	55	35.2	156.1	(117.6-203.2)
Female	31	24.8	125.0	(84.9-177.4)	Female	47	26.6	176.6	(129.7-234.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	10	11.6	86.0	(41.2-158.1)	Male	9	10.4	87.0	(39.7-165.1)
Female	12	10.3	116.9	(60.3-204.2)	Female	5	8.1	61.8	(19.9-144.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.2	nc	(nc-nc)	Male	31	34.5	89.7	(61.0-127.4)
Female	253	240.9	105.0	(92.5-118.8)	Female	28	31.2	89.7	(59.6-129.7)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	7	9.7	72.3	(29.0-149.0)	Male	19	24.6	77.3	(46.5-120.8)
<u>Colon / Rectum</u>					Female	12	12.3	97.7	(50.4-170.7)
Male	104	108.9	95.5	(78.1-115.8)	<u>Ovary</u>				
Female	106	101.1	104.8	(85.8-126.8)	Female	24	25.6	93.7	(60.0-139.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	17.4	74.9	(39.8-128.1)	Male	25	20.5	122.0	(78.9-180.0)
Female	5	4.9	102.2	(32.9-238.6)	Female	34	21.6	157.3	(108.9-219.8)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	4.3	nc	(nc-nc)	Male	355	282.8	125.5	(112.8-139.3)
Female	4	3.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	17	18.4	92.5	(53.8-148.1)
Male	33	27.8	118.6	(81.6-166.6)	Female	9	10.6	85.2	(38.9-161.8)
Female	19	17.7	107.5	(64.7-167.9)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.7	89.9	(32.8-195.6)
Male	10	11.9	83.8	(40.1-154.2)	<u>Thyroid</u>				
Female	6	3.2	188.3	(68.7-409.8)	Male	5	6.2	80.4	(25.9-187.6)
<u>Leukemia</u>					Female	8	19.3	41.4	(17.8-81.6)
Male	26	21.2	122.7	(80.1-179.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	31	16.9	182.9	(124.3-259.7)	Female	45	49.5	90.8	(66.2-121.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	13	12.9	101.0	(53.7-172.8)	Male	1011	930.6	108.6	(102.0-115.5)
Female	6	4.9	122.3	(44.6-266.2)	Female	878	823.4	106.6	(99.7-113.9)
<u>Lung and Bronchus</u>									
Male	135	136.9	98.6	(82.7-116.7)					
Female	123	118.6	103.7	(86.2-123.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Barre

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	5.3	nc	(nc-nc)	Male	4	2.9	nc	(nc-nc)
Female	0	1.8	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.0	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	Female	2	0.6	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	0.2	nc	(nc-nc)	Male	2	2.8	nc	(nc-nc)
Female	17	19.2	88.6	(51.6-141.8)	Female	2	2.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	0.9	nc	(nc-nc)	Male	2	2.0	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.9	nc	(nc-nc)
Male	4	8.0	nc	(nc-nc)	<u>Ovary</u>				
Female	2	7.6	nc	(nc-nc)	Female	2	2.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	1.3	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	1	1.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	14	20.3	68.8	(37.6-115.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	1.4	nc	(nc-nc)
Male	1	2.2	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
Female	3	1.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.8	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	1	1.9	nc	(nc-nc)
Male	2	1.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.4	nc	(nc-nc)	Female	0	3.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	1.0	nc	(nc-nc)	Male	50	69.8	71.6	(53.2-94.5)
Female	0	0.4	nc	(nc-nc)	Female	51	64.1	79.5	(59.2-104.5)
<u>Lung and Bronchus</u>									
Male	14	9.9	141.4	(77.2-237.3)					
Female	11	8.7	126.9	(63.2-227.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Becket

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.3	nc	(nc-nc)	Male	1	1.2	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	1	0.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	2	0.3	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	9	7.1	126.9	(57.9-240.9)	Female	1	0.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.3	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.3	nc	(nc-nc)
Male	3	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	2.4	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.6	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	2	9.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	0.6	nc	(nc-nc)
Male	1	1.0	nc	(nc-nc)	Female	0	0.2	nc	(nc-nc)
Female	0	0.5	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	1	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.1	nc	(nc-nc)	Male	1	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.7	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.4	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	31.2	60.9	(36.6-95.0)
Female	0	0.1	nc	(nc-nc)	Female	28	22.4	124.8	(82.9-180.4)
<u>Lung and Bronchus</u>									
Male	4	4.5	nc	(nc-nc)					
Female	3	3.1	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bedford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	16	20.0	79.9	(45.6-129.7)	Male	16	9.7	165.1	(94.3-268.1)
Female	5	5.6	89.1	(28.7-207.9)	Female	10	6.3	157.9	(75.6-290.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	3.2	nc	(nc-nc)	Male	3	2.8	nc	(nc-nc)
Female	3	2.4	nc	(nc-nc)	Female	1	1.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	15	9.5	158.4	(88.6-261.3)
Female	60	56.5	106.3	(81.1-136.8)	Female	5	7.1	70.3	(22.7-164.0)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	2.4	nc	(nc-nc)	Male	6	6.8	88.7	(32.4-193.1)
<u>Colon / Rectum</u>					Female	5	2.9	175.3	(56.5-409.1)
Male	20	29.8	67.2	(41.0-103.8)	<u>Ovary</u>				
Female	26	23.2	112.0	(73.2-164.2)	Female	9	6.0	150.6	(68.7-285.8)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.7	nc	(nc-nc)	Male	7	5.6	125.0	(50.1-257.6)
Female	1	1.1	nc	(nc-nc)	Female	4	4.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	1.2	nc	(nc-nc)	Male	65	76.4	85.1	(65.6-108.4)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	5.1	99.0	(31.9-231.0)
Male	4	7.6	nc	(nc-nc)	Female	2	2.5	nc	(nc-nc)
Female	4	4.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	2	1.8	nc	(nc-nc)
Male	1	3.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	0.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Leukemia</u>					Female	8	4.8	166.4	(71.6-327.8)
Male	2	5.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	4.0	nc	(nc-nc)	Female	16	11.5	139.1	(79.4-225.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	2	3.5	nc	(nc-nc)	Male	212	253.5	83.6	(72.7-95.7)
Female	0	1.1	nc	(nc-nc)	Female	198	190.4	104.0	(90.0-119.5)
<u>Lung and Bronchus</u>									
Male	24	37.1	64.7	(41.4-96.2)					
Female	18	26.2	68.8	(40.7-108.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Belchertown

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	11	10.3	106.6	(53.1-190.7)	Male	9	6.4	141.1	(64.4-267.9)
Female	5	3.5	144.2	(46.5-336.6)	Female	8	5.4	147.3	(63.4-290.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	2.4	nc	(nc-nc)	Male	4	1.6	nc	(nc-nc)
Female	5	2.0	248.2	(80.0-579.1)	Female	1	1.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	6	5.9	100.9	(36.8-219.6)
Female	39	44.2	88.2	(62.7-120.6)	Female	6	5.0	121.1	(44.2-263.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	2.3	nc	(nc-nc)	Male	4	4.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	2.1	nc	(nc-nc)
Male	16	16.1	99.4	(56.8-161.4)	<u>Ovary</u>				
Female	8	14.2	56.4	(24.3-111.2)	Female	3	4.5	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	5	2.7	186.0	(60.0-434.2)	Male	1	3.0	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	Female	4	3.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	1.1	nc	(nc-nc)	Male	32	41.9	76.4	(52.3-107.9)
Female	0	0.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	2.7	nc	(nc-nc)
Male	2	4.7	nc	(nc-nc)	Female	3	1.5	nc	(nc-nc)
Female	4	2.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	3	2.1	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.5	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	5	5.0	99.4	(32.0-232.0)
Male	3	3.6	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	2.8	nc	(nc-nc)	Female	9	8.5	105.4	(48.1-200.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	2.3	nc	(nc-nc)	Male	132	144.7	91.2	(76.3-108.2)
Female	0	0.7	nc	(nc-nc)	Female	135	137.4	98.2	(82.4-116.3)
<u>Lung and Bronchus</u>									
Male	15	19.9	75.4	(42.2-124.4)					
Female	16	17.3	92.6	(52.9-150.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bellingham

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	13	12.9	100.5	(53.5-171.9)	Male	8	7.9	101.4	(43.7-199.8)
Female	3	4.5	nc	(nc-nc)	Female	10	6.6	150.7	(72.2-277.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.9	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	2	2.5	nc	(nc-nc)	Female	0	1.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.4	nc	(nc-nc)	Male	6	7.3	82.0	(29.9-178.5)
Female	39	54.6	71.4	(50.7-97.6)	Female	7	6.2	112.3	(45.0-231.3)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	2.7	nc	(nc-nc)	Male	7	5.7	123.6	(49.5-254.7)
<u>Colon / Rectum</u>					Female	3	2.6	nc	(nc-nc)
Male	23	20.1	114.4	(72.5-171.7)	<u>Ovary</u>				
Female	11	17.8	61.9	(30.9-110.8)	Female	7	5.6	124.5	(49.9-256.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	3.5	nc	(nc-nc)	Male	1	3.8	nc	(nc-nc)
Female	2	0.9	nc	(nc-nc)	Female	5	3.8	133.0	(42.9-310.4)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.3	nc	(nc-nc)	Male	53	57.1	92.9	(69.6-121.5)
Female	1	1.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	7	3.4	208.8	(83.6-430.2)
Male	5	6.0	83.2	(26.8-194.1)	Female	2	1.8	nc	(nc-nc)
Female	3	3.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.6	nc	(nc-nc)
Male	5	2.5	202.0	(65.1-471.4)	<u>Thyroid</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.8	nc	(nc-nc)
<u>Leukemia</u>					Female	3	5.9	nc	(nc-nc)
Male	4	4.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	5	3.5	143.5	(46.2-334.8)	Female	11	11.1	99.3	(49.5-177.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	2.8	nc	(nc-nc)	Male	190	186.0	102.1	(88.1-117.7)
Female	0	0.9	nc	(nc-nc)	Female	155	172.3	90.0	(76.4-105.3)
<u>Lung and Bronchus</u>									
Male	33	25.7	128.4	(88.4-180.4)					
Female	26	22.7	114.3	(74.7-167.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Belmont

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	29	30.5	95.2	(63.7-136.7)	Male	18	15.5	116.1	(68.8-183.5)
Female	8	11.6	69.1	(29.7-136.1)	Female	24	13.2	181.3	(116.1-269.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	5	5.3	94.3	(30.4-220.0)	Male	2	4.4	nc	(nc-nc)
Female	5	5.0	99.7	(32.1-232.6)	Female	0	3.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	0.9	nc	(nc-nc)	Male	13	15.0	86.6	(46.0-148.0)
Female	115	115.6	99.5	(82.1-119.4)	Female	25	14.8	168.7	(109.1-249.0)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	5.0	nc	(nc-nc)	Male	7	10.9	64.3	(25.8-132.5)
<u>Colon / Rectum</u>					Female	9	5.8	153.9	(70.2-292.3)
Male	45	45.7	98.5	(71.8-131.7)	<u>Ovary</u>				
Female	47	48.5	97.0	(71.3-129.0)	Female	19	12.3	154.4	(92.9-241.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	7.4	108.6	(46.8-214.0)	Male	12	8.6	139.3	(71.9-243.3)
Female	4	2.3	nc	(nc-nc)	Female	12	10.2	117.7	(60.8-205.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	2.1	nc	(nc-nc)	Male	102	118.6	86.0	(70.1-104.4)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	7.8	64.5	(20.8-150.4)
Male	5	12.0	41.7	(13.5-97.4)	Female	3	5.2	nc	(nc-nc)
Female	4	8.2	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	7	3.6	195.2	(78.2-402.2)
Male	3	5.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.4	nc	(nc-nc)	Male	3	2.9	nc	(nc-nc)
<u>Leukemia</u>					Female	11	10.2	107.6	(53.6-192.5)
Male	7	9.2	76.3	(30.6-157.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	8.3	157.3	(83.7-269.0)	Female	19	23.3	81.7	(49.2-127.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	5.6	nc	(nc-nc)	Male	327	394.5	82.9	(74.1-92.4)
Female	3	2.3	nc	(nc-nc)	Female	394	392.8	100.3	(90.6-110.7)
<u>Lung and Bronchus</u>									
Male	26	56.7	45.9	(29.9-67.2)					
Female	46	53.8	85.5	(62.6-114.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berkley

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.7	nc	(nc-nc)	Male	2	2.6	nc	(nc-nc)
Female	2	1.2	nc	(nc-nc)	Female	2	2.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	1.0	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
Female	2	0.8	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	2.3	nc	(nc-nc)
Female	16	16.5	96.9	(55.3-157.3)	Female	4	1.8	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.9	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	0.8	nc	(nc-nc)
Male	8	5.9	134.6	(57.9-265.2)	<u>Ovary</u>				
Female	3	4.8	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	1.0	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	0.2	nc	(nc-nc)	Female	1	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.5	nc	(nc-nc)	Male	19	16.8	113.0	(68.0-176.5)
Female	0	0.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	1.0	nc	(nc-nc)
Male	1	1.9	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.0	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	1	0.6	nc	(nc-nc)
<u>Leukemia</u>					Female	4	2.1	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	1.1	nc	(nc-nc)	Female	5	3.2	157.0	(50.6-366.5)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	58	56.3	103.0	(78.2-133.2)
Female	0	0.2	nc	(nc-nc)	Female	53	50.3	105.5	(79.0-137.9)
<u>Lung and Bronchus</u>									
Male	8	7.5	106.5	(45.9-209.9)					
Female	4	6.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Berlin

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	2.6	nc	(nc-nc)	Male	1	1.5	nc	(nc-nc)
Female	0	0.8	nc	(nc-nc)	Female	1	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.5	nc	(nc-nc)	Male	1	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.4	nc	(nc-nc)
Female	13	9.7	134.2	(71.4-229.5)	Female	1	1.1	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	5	4.0	126.2	(40.7-294.6)	<u>Ovary</u>				
Female	7	3.4	206.1	(82.6-424.7)	Female	1	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	2	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	11	11.1	98.7	(49.2-176.6)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.7	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.4	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	3	0.9	nc	(nc-nc)
Male	1	0.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.6	nc	(nc-nc)	Female	3	2.0	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	35.9	89.2	(61.0-126.0)
Female	1	0.2	nc	(nc-nc)	Female	39	31.0	125.7	(89.4-171.9)
<u>Lung and Bronchus</u>									
Male	2	5.0	nc	(nc-nc)					
Female	4	4.2	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bernardston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	2.8	nc	(nc-nc)	Male	2	1.5	nc	(nc-nc)
Female	3	0.9	nc	(nc-nc)	Female	2	1.1	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.5	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	1.4	nc	(nc-nc)
Female	13	10.0	129.8	(69.1-222.0)	Female	2	1.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.4	nc	(nc-nc)	Male	0	1.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.5	nc	(nc-nc)
Male	7	4.3	164.3	(65.8-338.6)	<u>Ovary</u>				
Female	5	3.9	128.0	(41.2-298.6)	Female	2	1.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.7	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.2	nc	(nc-nc)	Male	11	11.4	96.7	(48.2-173.1)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	0.7	nc	(nc-nc)
Male	1	1.2	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.7	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	0	0.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
<u>Leukemia</u>					Female	1	0.9	nc	(nc-nc)
Male	0	0.9	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.7	nc	(nc-nc)	Female	7	2.0	347.6	(139.3-716.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.5	nc	(nc-nc)	Male	32	37.3	85.8	(58.7-121.1)
Female	0	0.2	nc	(nc-nc)	Female	42	33.0	127.2	(91.7-171.9)
<u>Lung and Bronchus</u>									
Male	3	5.4	nc	(nc-nc)					
Female	3	4.5	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Beverly

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	48	44.0	109.2	(80.5-144.8)	Male	26	23.4	111.0	(72.5-162.6)
Female	18	17.8	100.9	(59.8-159.4)	Female	21	20.3	103.5	(64.0-158.2)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	16	8.2	195.9	(111.9-318.1)	Male	7	6.4	110.2	(44.1-227.0)
Female	6	7.8	77.3	(28.2-168.3)	Female	4	5.8	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.4	nc	(nc-nc)	Male	18	22.5	80.1	(47.4-126.6)
Female	173	174.0	99.5	(85.2-115.4)	Female	25	22.8	109.6	(70.9-161.8)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	5	7.5	66.3	(21.4-154.7)	Male	16	16.3	98.2	(56.1-159.4)
<u>Colon / Rectum</u>					Female	12	8.9	134.5	(69.4-235.0)
Male	55	66.4	82.8	(62.4-107.8)	<u>Ovary</u>				
Female	77	75.0	102.6	(81.0-128.2)	Female	25	18.7	133.7	(86.5-197.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	10.8	92.8	(44.4-170.6)	Male	14	12.5	111.9	(61.1-187.8)
Female	2	3.6	nc	(nc-nc)	Female	15	15.8	95.0	(53.1-156.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	3.5	142.4	(45.9-332.4)	Male	133	173.1	76.8	(64.3-91.0)
Female	2	3.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	5	11.2	44.6	(14.4-104.0)
Male	21	17.9	117.4	(72.7-179.5)	Female	3	8.1	nc	(nc-nc)
Female	20	12.6	159.1	(97.1-245.7)	<u>Testis</u>				
<u>Larynx</u>					Male	6	6.3	95.8	(35.0-208.6)
Male	11	7.5	147.0	(73.3-263.1)	<u>Thyroid</u>				
Female	4	2.2	nc	(nc-nc)	Male	5	4.7	107.1	(34.5-249.8)
<u>Leukemia</u>					Female	11	15.8	69.7	(34.8-124.8)
Male	12	13.7	87.6	(45.2-153.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	12.9	92.8	(47.9-162.2)	Female	36	34.7	103.8	(72.7-143.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	8.4	83.7	(33.5-172.4)	Male	531	580.3	91.5	(83.9-99.6)
Female	4	3.6	nc	(nc-nc)	Female	616	599.7	102.7	(94.8-111.2)
<u>Lung and Bronchus</u>									
Male	77	82.8	92.9	(73.3-116.2)					
Female	90	82.0	109.7	(88.2-134.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Billerica

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	34	30.2	112.4	(77.9-157.1)	Male	20	19.5	102.7	(62.7-158.6)
Female	8	10.6	75.4	(32.5-148.6)	Female	12	16.1	74.7	(38.6-130.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	7.4	nc	(nc-nc)	Male	9	4.6	193.6	(88.4-367.6)
Female	6	6.0	100.6	(36.7-218.9)	Female	6	3.5	173.4	(63.3-377.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	1.0	nc	(nc-nc)	Male	17	17.9	95.0	(55.3-152.1)
Female	127	132.5	95.8	(79.9-114.0)	Female	7	14.8	47.2	(18.9-97.2)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	3	6.6	nc	(nc-nc)	Male	12	14.2	84.7	(43.7-148.0)
<u>Colon / Rectum</u>					Female	12	6.3	191.9	(99.0-335.2)
Male	42	47.7	88.1	(63.5-119.1)	<u>Ovary</u>				
Female	43	42.3	101.6	(73.5-136.8)	Female	13	13.6	95.4	(50.8-163.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	13	8.4	155.5	(82.7-266.0)	Male	6	9.1	65.9	(24.1-143.4)
Female	2	2.1	nc	(nc-nc)	Female	7	8.9	79.1	(31.7-163.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	3	3.5	nc	(nc-nc)	Male	166	137.7	120.6	(102.9-140.4)
Female	4	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	7.9	nc	(nc-nc)
Male	19	14.7	129.0	(77.6-201.4)	Female	0	4.3	nc	(nc-nc)
Female	6	8.6	69.4	(25.4-151.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	6.9	72.2	(23.3-168.4)
Male	3	6.1	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.6	nc	(nc-nc)	Male	5	4.6	109.3	(35.2-255.0)
<u>Leukemia</u>					Female	18	14.4	124.7	(73.8-197.0)
Male	7	10.8	65.1	(26.1-134.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	13	8.4	155.6	(82.8-266.1)	Female	21	27.1	77.5	(47.9-118.4)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	6.9	nc	(nc-nc)	Male	489	448.6	109.0	(99.6-119.1)
Female	7	2.2	321.0	(128.6-661.5)	Female	423	414.0	102.2	(92.7-112.4)
<u>Lung and Bronchus</u>									
Male	80	60.7	131.9	(104.6-164.2)					
Female	75	53.3	140.7	(110.6-176.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Blackstone

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	8	7.4	107.8	(46.4-212.4)	Male	3	4.4	nc	(nc-nc)
Female	2	2.7	nc	(nc-nc)	Female	1	3.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.6	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.4	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.2	nc	(nc-nc)	Male	0	4.1	nc	(nc-nc)
Female	26	30.7	84.7	(55.3-124.0)	Female	3	3.7	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.5	nc	(nc-nc)	Male	1	3.1	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	3	1.5	nc	(nc-nc)
Male	9	11.4	78.9	(36.0-149.7)	<u>Ovary</u>				
Female	12	10.9	109.8	(56.7-191.8)	Female	5	3.2	156.5	(50.4-365.1)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.9	nc	(nc-nc)	Male	1	2.2	nc	(nc-nc)
Female	4	0.5	nc	(nc-nc)	Female	0	2.3	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	0.8	nc	(nc-nc)	Male	18	30.2	59.7	(35.4-94.4)
Female	1	0.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	1.9	nc	(nc-nc)
Male	7	3.3	214.0	(85.7-440.9)	Female	2	1.1	nc	(nc-nc)
Female	1	2.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.5	nc	(nc-nc)
Male	0	1.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.3	nc	(nc-nc)
Male	6	2.5	236.7	(86.4-515.2)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	2.1	nc	(nc-nc)	Female	1	6.1	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	1.5	nc	(nc-nc)	Male	83	102.6	80.9	(64.4-100.3)
Female	1	0.5	nc	(nc-nc)	Female	89	99.6	89.3	(71.7-109.9)
<u>Lung and Bronchus</u>									
Male	19	14.2	134.0	(80.7-209.3)					
Female	15	13.2	113.2	(63.3-186.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Blandford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	1	1.3	nc	(nc-nc)	Male	0	0.8	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.1	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.0	nc	(nc-nc)	Male	1	0.7	nc	(nc-nc)
Female	4	4.7	nc	(nc-nc)	Female	1	0.5	nc	(nc-nc)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	1	0.2	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
<b><u>Colon / Rectum</u></b>					Female	0	0.2	nc	(nc-nc)
Male	0	2.0	nc	(nc-nc)	<b><u>Ovary</u></b>				
Female	1	1.4	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	0	0.1	nc	(nc-nc)	Male	5	5.6	89.8	(28.9-209.5)
Female	0	0.1	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	1	0.3	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	Female	0	0.1	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	0	0.2	nc	(nc-nc)
Male	0	0.2	nc	(nc-nc)	<b><u>Thyroid</u></b>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	0	0.5	nc	(nc-nc)
Male	0	0.4	nc	(nc-nc)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	1	0.3	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	0	0.3	nc	(nc-nc)	Male	11	18.0	61.1	(30.4-109.3)
Female	0	0.1	nc	(nc-nc)	Female	15	14.3	104.9	(58.7-173.1)
<b><u>Lung and Bronchus</u></b>									
Male	1	2.5	nc	(nc-nc)					
Female	3	1.8	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bolton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	3.1	nc	(nc-nc)	Male	0	2.1	nc	(nc-nc)
Female	0	1.0	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.8	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	Female	2	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	1.9	nc	(nc-nc)
Female	19	14.3	132.8	(79.9-207.4)	Female	0	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	2	1.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	2	5.1	nc	(nc-nc)	<u>Ovary</u>				
Female	7	3.8	182.5	(73.1-376.0)	Female	2	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	2	0.9	nc	(nc-nc)	Male	4	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.8	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	12	14.7	81.6	(42.1-142.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	0.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.7	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	2	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.6	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	3	2.8	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.8	nc	(nc-nc)	Male	42	47.8	87.8	(63.3-118.7)
Female	0	0.2	nc	(nc-nc)	Female	43	41.7	103.1	(74.6-138.8)
<u>Lung and Bronchus</u>									
Male	5	6.4	78.6	(25.3-183.3)					
Female	4	5.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	349	456.2	76.5	(68.7-85.0)	Male	225	265.7	84.7	(74.0-96.5)
Female	156	182.2	85.6	(72.7-100.2)	Female	190	247.7	76.7	(66.2-88.4)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	81	100.0	81.0	(64.3-100.7)	Male	69	66.7	103.4	(80.5-130.9)
Female	81	92.0	88.0	(69.9-109.4)	Female	69	59.4	116.2	(90.4-147.1)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	18	14.4	124.8	(73.9-197.2)	Male	277	253.9	109.1	(96.6-122.7)
Female	1814	1912.6	94.8	(90.5-99.3)	Female	242	246.0	98.4	(86.4-111.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	124	94.6	131.1	(109.1-156.3)	Male	236	177.6	132.9	(116.5-151.0)
<u>Colon / Rectum</u>					Female	98	97.7	100.3	(81.4-122.2)
Male	715	695.5	102.8	(95.4-110.6)	<u>Ovary</u>				
Female	845	750.8	112.5	(105.1-120.4)	Female	190	206.2	92.1	(79.5-106.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	104	113.6	91.5	(74.8-110.9)	Male	141	130.6	108.0	(90.9-127.3)
Female	40	35.9	111.3	(79.5-151.6)	Female	149	158.1	94.3	(79.7-110.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	49	55.9	87.7	(64.9-116.0)	Male	1995	1824.7	109.3	(104.6-114.2)
Female	55	51.9	106.0	(79.8-137.9)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	167	118.1	141.4	(120.8-164.6)
Male	203	192.5	105.5	(91.5-121.0)	Female	137	80.0	171.2	(143.8-202.4)
Female	147	135.2	108.7	(91.8-127.8)	<u>Testis</u>				
<u>Larynx</u>					Male	83	110.0	75.5	(60.1-93.6)
Male	99	79.4	124.6	(101.3-151.7)	<u>Thyroid</u>				
Female	25	24.0	104.1	(67.3-153.7)	Male	67	60.1	111.5	(86.4-141.6)
<u>Leukemia</u>					Female	258	217.7	118.5	(104.5-133.9)
Male	150	155.6	96.4	(81.6-113.1)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	119	140.0	85.0	(70.4-101.7)	Female	369	385.0	95.8	(86.3-106.1)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	167	89.4	186.8	(159.6-217.4)	Male	6695	6254.0	107.1	(104.5-109.6)
Female	62	37.3	166.1	(127.4-213.0)	Female	6625	6503.0	101.9	(99.4-104.4)
<u>Lung and Bronchus</u>									
Male	961	864.2	111.2	(104.3-118.5)					
Female	899	864.7	104.0	(97.3-111.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bourne

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	23	24.7	93.1	(59.0-139.6)	Male	17	12.4	137.6	(80.1-220.4)
Female	8	8.5	93.9	(40.4-185.0)	Female	12	9.5	126.8	(65.4-221.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	4.2	nc	(nc-nc)	Male	7	3.5	198.6	(79.6-409.3)
Female	4	3.7	nc	(nc-nc)	Female	5	2.8	179.6	(57.9-419.2)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	7	12.0	58.2	(23.3-119.9)
Female	94	83.9	112.0	(90.5-137.0)	Female	12	10.8	111.1	(57.3-194.0)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	3.5	nc	(nc-nc)	Male	10	8.7	115.4	(55.2-212.2)
<u>Colon / Rectum</u>					Female	5	4.3	116.5	(37.6-272.0)
Male	51	36.9	138.0	(102.8-181.5)	<u>Ovary</u>				
Female	50	34.7	144.1	(107.0-190.0)	Female	10	9.0	111.7	(53.5-205.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	6.0	150.3	(68.6-285.3)	Male	4	7.0	nc	(nc-nc)
Female	1	1.7	nc	(nc-nc)	Female	5	7.4	67.6	(21.8-157.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	4	1.8	nc	(nc-nc)	Male	140	98.8	141.6	(119.2-167.1)
Female	1	1.4	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	6	6.2	96.8	(35.3-210.6)
Male	9	9.7	92.6	(42.3-175.8)	Female	4	3.6	nc	(nc-nc)
Female	7	6.1	114.2	(45.8-235.4)	<u>Testis</u>				
<u>Larynx</u>					Male	1	2.8	nc	(nc-nc)
Male	4	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	1	1.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
<u>Leukemia</u>					Female	6	7.1	85.0	(31.0-185.0)
Male	9	7.4	121.6	(55.5-230.9)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	6	5.9	100.8	(36.8-219.5)	Female	25	17.4	143.4	(92.8-211.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	4.5	177.8	(76.5-350.3)	Male	389	322.3	120.7	(109.0-133.3)
Female	2	1.7	nc	(nc-nc)	Female	347	286.3	121.2	(108.8-134.7)
<u>Lung and Bronchus</u>									
Male	50	47.0	106.5	(79.0-140.4)					
Female	62	40.8	152.0	(116.5-194.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boxborough

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.9	nc	(nc-nc)	Male	2	2.2	nc	(nc-nc)
Female	1	0.9	nc	(nc-nc)	Female	2	1.8	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	1	2.0	nc	(nc-nc)
Female	13	14.2	91.5	(48.7-156.5)	Female	2	1.4	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	0.8	nc	(nc-nc)	Male	0	1.6	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	1	4.8	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.4	nc	(nc-nc)	Female	1	1.4	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.9	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.4	nc	(nc-nc)	Male	11	13.2	83.4	(41.6-149.2)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.8	nc	(nc-nc)
Male	1	1.6	nc	(nc-nc)	Female	1	0.3	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.8	nc	(nc-nc)
Male	0	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	5	0.5	909.4	(293.1-2122.2)
<u>Leukemia</u>					Female	5	1.8	276.5	(89.1-645.3)
Male	1	1.2	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	0	0.8	nc	(nc-nc)	Female	4	2.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.8	nc	(nc-nc)	Male	32	45.4	70.5	(48.2-99.5)
Female	0	0.2	nc	(nc-nc)	Female	42	40.5	103.8	(74.8-140.3)
<u>Lung and Bronchus</u>									
Male	4	5.8	nc	(nc-nc)					
Female	3	4.6	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

## Boxford

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	2	7.5	nc	(nc-nc)	Male	6	4.5	132.7	(48.5-288.9)
Female	3	2.2	nc	(nc-nc)	Female	4	3.4	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	1.7	nc	(nc-nc)	Male	1	1.1	nc	(nc-nc)
Female	2	1.3	nc	(nc-nc)	Female	1	0.7	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.3	nc	(nc-nc)	Male	7	4.2	167.1	(66.9-344.3)
Female	36	30.2	119.3	(83.6-165.2)	Female	0	3.2	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	1.4	nc	(nc-nc)	Male	6	3.5	173.9	(63.5-378.5)
<u>Colon / Rectum</u>					Female	4	1.4	nc	(nc-nc)
Male	16	11.8	135.6	(77.5-220.2)	<u>Ovary</u>				
Female	7	9.0	78.0	(31.3-160.8)	Female	4	3.0	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	2.1	nc	(nc-nc)	Male	0	2.3	nc	(nc-nc)
Female	1	0.4	nc	(nc-nc)	Female	3	1.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.7	nc	(nc-nc)	Male	32	33.8	94.6	(64.7-133.5)
Female	0	0.5	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	2	2.0	nc	(nc-nc)
Male	3	3.6	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
Female	0	1.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	1.1	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.4	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
<u>Leukemia</u>					Female	2	3.0	nc	(nc-nc)
Male	3	2.5	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	1.8	nc	(nc-nc)	Female	6	6.1	99.2	(36.2-215.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	1.7	nc	(nc-nc)	Male	94	108.6	86.6	(70.0-105.9)
Female	1	0.5	nc	(nc-nc)	Female	94	90.6	103.8	(83.9-127.0)
<u>Lung and Bronchus</u>									
Male	8	15.0	53.3	(22.9-105.0)					
Female	10	11.5	87.0	(41.6-159.9)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Boylston

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	3	4.3	nc	(nc-nc)	Male	5	2.4	204.6	(65.9-477.4)
Female	4	1.4	nc	(nc-nc)	Female	0	1.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.9	nc	(nc-nc)	Male	0	0.6	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	3	2.3	nc	(nc-nc)
Female	18	16.4	110.0	(65.2-173.9)	Female	3	1.9	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.7	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.8	nc	(nc-nc)
Male	8	6.6	121.6	(52.4-239.6)	<u>Ovary</u>				
Female	7	5.5	126.7	(50.8-261.1)	Female	2	1.7	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	0	1.1	nc	(nc-nc)	Male	1	1.3	nc	(nc-nc)
Female	0	0.3	nc	(nc-nc)	Female	0	1.2	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.4	nc	(nc-nc)	Male	24	18.4	130.1	(83.3-193.6)
Female	0	0.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	1	1.1	nc	(nc-nc)
Male	2	1.9	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
Female	0	1.1	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.6	nc	(nc-nc)
Male	0	0.8	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
<u>Leukemia</u>					Female	3	1.6	nc	(nc-nc)
Male	2	1.4	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	1.0	nc	(nc-nc)	Female	4	3.3	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.9	nc	(nc-nc)	Male	57	59.6	95.6	(72.4-123.9)
Female	1	0.3	nc	(nc-nc)	Female	48	51.7	92.9	(68.5-123.2)
<u>Lung and Bronchus</u>									
Male	6	8.4	71.8	(26.2-156.3)					
Female	3	7.0	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Braintree

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	43.6	117.0	(87.1-153.8)	Male	30	21.9	136.8	(92.3-195.3)
Female	16	17.0	94.0	(53.7-152.7)	Female	23	18.5	124.3	(78.8-186.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	6	7.5	80.1	(29.2-174.3)	Male	2	6.2	nc	(nc-nc)
Female	7	7.1	98.5	(39.5-203.0)	Female	4	5.5	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	1.3	nc	(nc-nc)	Male	19	21.3	89.2	(53.7-139.4)
Female	156	163.7	95.3	(80.9-111.5)	Female	23	21.4	107.4	(68.0-161.1)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	10	6.7	148.5	(71.1-273.1)	Male	17	15.4	110.5	(64.3-176.9)
<u>Colon / Rectum</u>					Female	6	8.4	71.2	(26.0-155.1)
Male	84	65.3	128.7	(102.7-159.4)	<u>Ovary</u>				
Female	86	70.0	122.8	(98.2-151.7)	Female	19	17.5	108.5	(65.3-169.4)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	8	10.6	75.7	(32.6-149.2)	Male	9	12.3	73.1	(33.3-138.7)
Female	3	3.4	nc	(nc-nc)	Female	12	14.9	80.6	(41.6-140.7)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	2	3.0	nc	(nc-nc)	Male	141	173.0	81.5	(68.6-96.1)
Female	4	2.7	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	11	11.0	100.1	(49.9-179.1)
Male	19	17.2	110.3	(66.4-172.3)	Female	5	7.4	67.4	(21.7-157.2)
Female	8	12.0	66.7	(28.7-131.3)	<u>Testis</u>				
<u>Larynx</u>					Male	3	5.0	nc	(nc-nc)
Male	3	7.3	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	2.1	nc	(nc-nc)	Male	4	4.1	nc	(nc-nc)
<u>Leukemia</u>					Female	12	13.7	87.7	(45.3-153.3)
Male	14	13.1	107.1	(58.5-179.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	12	11.9	101.2	(52.2-176.7)	Female	31	33.5	92.4	(62.8-131.2)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	7	7.9	88.1	(35.3-181.5)	Male	556	567.6	98.0	(90.0-106.5)
Female	2	3.4	nc	(nc-nc)	Female	557	564.0	98.8	(90.7-107.3)
<u>Lung and Bronchus</u>									
Male	82	82.5	99.4	(79.1-123.4)					
Female	75	80.0	93.8	(73.8-117.6)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brewster

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	21	19.4	108.2	(67.0-165.4)	Male	13	8.7	149.5	(79.6-255.8)
Female	10	6.5	154.2	(73.8-283.6)	Female	12	6.3	189.8	(97.9-331.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	2.7	nc	(nc-nc)	Male	2	2.7	nc	(nc-nc)
Female	7	2.5	285.5	(114.4-588.2)	Female	3	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	0.6	nc	(nc-nc)	Male	7	8.7	80.6	(32.3-166.1)
Female	78	58.8	132.6	(104.8-165.5)	Female	9	7.9	114.1	(52.1-216.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	2.2	nc	(nc-nc)	Male	10	6.0	167.7	(80.3-308.4)
<u>Colon / Rectum</u>					Female	2	3.1	nc	(nc-nc)
Male	30	28.4	105.5	(71.2-150.6)	<u>Ovary</u>				
Female	18	26.9	66.9	(39.6-105.7)	Female	10	6.3	157.8	(75.5-290.2)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	3	4.4	nc	(nc-nc)	Male	5	5.3	93.9	(30.3-219.1)
Female	4	1.3	nc	(nc-nc)	Female	6	5.7	104.5	(38.2-227.5)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.9	nc	(nc-nc)	Male	88	70.6	124.7	(100.0-153.6)
Female	0	0.8	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	4.8	nc	(nc-nc)
Male	7	6.9	101.7	(40.7-209.6)	Female	2	2.9	nc	(nc-nc)
Female	2	4.4	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	1.2	nc	(nc-nc)
Male	4	3.0	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.8	nc	(nc-nc)	Male	0	1.4	nc	(nc-nc)
<u>Leukemia</u>					Female	3	4.2	nc	(nc-nc)
Male	8	5.3	149.7	(64.5-295.0)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	3	4.3	nc	(nc-nc)	Female	12	12.0	100.1	(51.6-174.8)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	3.2	nc	(nc-nc)	Male	270	235.9	114.5	(101.2-129.0)
Female	0	1.3	nc	(nc-nc)	Female	229	206.4	111.0	(97.1-126.3)
<u>Lung and Bronchus</u>									
Male	43	35.3	121.8	(88.1-164.0)					
Female	27	29.8	90.5	(59.6-131.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Bridgewater

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	17	18.9	89.7	(52.3-143.7)	Male	18	12.4	144.9	(85.8-229.0)
Female	6	6.4	93.6	(34.2-203.8)	Female	11	9.3	118.6	(59.1-212.3)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	3	4.7	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
Female	7	3.5	198.5	(79.5-408.9)	Female	0	2.1	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.6	nc	(nc-nc)	Male	13	11.5	113.1	(60.1-193.4)
Female	84	74.6	112.5	(89.8-139.3)	Female	11	8.9	123.8	(61.7-221.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	4	3.7	nc	(nc-nc)	Male	4	8.7	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	2	3.6	nc	(nc-nc)
Male	35	29.9	117.2	(81.6-163.0)	<u>Ovary</u>				
Female	25	26.1	95.6	(61.9-141.1)	Female	9	7.9	114.6	(52.3-217.6)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	6	5.1	117.6	(42.9-256.0)	Male	6	5.7	106.1	(38.8-231.0)
Female	0	1.3	nc	(nc-nc)	Female	5	5.5	91.3	(29.4-213.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	2.5	nc	(nc-nc)	Male	77	81.4	94.6	(74.7-118.3)
Female	2	1.9	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	5.0	nc	(nc-nc)
Male	13	9.0	143.9	(76.5-246.1)	Female	0	2.7	nc	(nc-nc)
Female	6	5.0	119.0	(43.5-259.1)	<u>Testis</u>				
<u>Larynx</u>					Male	5	5.0	99.8	(32.2-232.9)
Male	5	3.7	136.8	(44.1-319.3)	<u>Thyroid</u>				
Female	1	0.9	nc	(nc-nc)	Male	3	3.0	nc	(nc-nc)
<u>Leukemia</u>					Female	13	8.3	156.3	(83.1-267.3)
Male	3	6.8	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	7	5.1	137.3	(55.0-282.9)	Female	12	14.9	80.5	(41.5-140.6)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	3	4.3	nc	(nc-nc)	Male	275	276.9	99.3	(87.9-111.8)
Female	1	1.3	nc	(nc-nc)	Female	239	241.6	98.9	(86.8-112.3)
<u>Lung and Bronchus</u>									
Male	32	37.3	85.8	(58.7-121.1)					
Female	26	31.4	82.9	(54.1-121.5)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brimfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	6	3.4	174.1	(63.6-378.9)	Male	0	2.0	nc	(nc-nc)
Female	2	1.1	nc	(nc-nc)	Female	2	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	1	0.7	nc	(nc-nc)	Male	1	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	1	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	11	12.8	86.0	(42.9-153.8)	Female	0	1.5	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	3	1.5	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	5	5.3	93.9	(30.3-219.2)	<u>Ovary</u>				
Female	2	4.4	nc	(nc-nc)	Female	0	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	0	0.2	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	1	0.3	nc	(nc-nc)	Male	10	14.5	68.9	(33.0-126.7)
Female	1	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.9	nc	(nc-nc)
Male	1	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	1	0.8	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	0	1.3	nc	(nc-nc)
Male	1	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	2	0.8	nc	(nc-nc)	Female	1	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.7	nc	(nc-nc)	Male	48	47.7	100.6	(74.2-133.4)
Female	0	0.2	nc	(nc-nc)	Female	32	40.6	78.9	(54.0-111.4)
<u>Lung and Bronchus</u>									
Male	9	6.7	135.3	(61.7-256.8)					
Female	3	5.3	nc	(nc-nc)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brockton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	72	86.4	83.3	(65.2-104.9)	Male	39	47.6	82.0	(58.3-112.1)
Female	28	33.0	85.0	(56.5-122.8)	Female	41	41.6	98.6	(70.8-133.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	21	17.7	118.8	(73.5-181.7)	Male	11	12.6	87.2	(43.5-156.0)
Female	19	16.1	117.9	(71.0-184.1)	Female	9	10.7	84.0	(38.3-159.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	1	2.7	nc	(nc-nc)	Male	41	45.6	89.9	(64.5-121.9)
Female	272	346.5	78.5	(69.5-88.4)	Female	36	43.5	82.7	(57.9-114.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	22	15.9	138.4	(86.7-209.6)	Male	40	33.3	120.2	(85.8-163.7)
<u>Colon / Rectum</u>					Female	23	17.4	132.2	(83.8-198.4)
Male	133	131.4	101.2	(84.8-120.0)	<u>Ovary</u>				
Female	127	136.0	93.3	(77.8-111.1)	Female	32	36.9	86.8	(59.4-122.5)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	32	21.6	148.2	(101.4-209.3)	Male	28	24.8	112.8	(74.9-163.0)
Female	11	6.5	168.8	(84.2-302.1)	Female	33	28.6	115.4	(79.4-162.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	8.0	75.4	(27.5-164.1)	Male	318	348.8	91.2	(81.4-101.8)
Female	3	7.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	30	22.2	135.1	(91.1-192.9)
Male	34	36.2	93.8	(65.0-131.1)	Female	21	14.4	145.4	(90.0-222.3)
Female	14	24.4	57.4	(31.4-96.3)	<u>Testis</u>				
<u>Larynx</u>					Male	11	14.4	76.6	(38.2-137.0)
Male	15	15.1	99.3	(55.5-163.8)	<u>Thyroid</u>				
Female	7	4.3	161.0	(64.5-331.8)	Male	10	9.9	100.8	(48.3-185.4)
<u>Leukemia</u>					Female	46	34.5	133.5	(97.7-178.1)
Male	38	28.4	133.9	(94.7-183.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	25	25.0	100.0	(64.7-147.6)	Female	66	70.1	94.1	(72.8-119.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	21	16.8	125.0	(77.4-191.2)	Male	1188	1166.7	101.8	(96.1-107.8)
Female	5	6.7	74.6	(24.0-174.0)	Female	1116	1162.4	96.0	(90.5-101.8)
<u>Lung and Bronchus</u>									
Male	188	164.1	114.6	(98.8-132.2)					
Female	182	156.1	116.6	(100.2-134.8)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookfield

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	4	3.5	nc	(nc-nc)	Male	0	1.9	nc	(nc-nc)
Female	1	1.2	nc	(nc-nc)	Female	1	1.5	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	2	0.7	nc	(nc-nc)	Male	0	0.5	nc	(nc-nc)
Female	1	0.6	nc	(nc-nc)	Female	0	0.4	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	0	1.8	nc	(nc-nc)
Female	14	12.9	108.1	(59.1-181.4)	Female	2	1.6	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	1	0.6	nc	(nc-nc)	Male	0	1.3	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	0	0.6	nc	(nc-nc)
Male	4	5.3	nc	(nc-nc)	<u>Ovary</u>				
Female	4	4.8	nc	(nc-nc)	Female	2	1.3	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.9	nc	(nc-nc)	Male	0	1.0	nc	(nc-nc)
Female	1	0.2	nc	(nc-nc)	Female	0	1.0	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.3	nc	(nc-nc)	Male	13	14.0	92.6	(49.3-158.3)
Female	0	0.2	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	3	0.9	nc	(nc-nc)
Male	4	1.5	nc	(nc-nc)	Female	0	0.5	nc	(nc-nc)
Female	0	0.9	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	1	0.5	nc	(nc-nc)
Male	1	0.6	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.2	nc	(nc-nc)	Male	0	0.4	nc	(nc-nc)
<u>Leukemia</u>					Female	2	1.2	nc	(nc-nc)
Male	0	1.1	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.9	nc	(nc-nc)	Female	2	2.6	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	1	0.7	nc	(nc-nc)	Male	47	46.8	100.4	(73.8-133.5)
Female	0	0.2	nc	(nc-nc)	Female	44	42.5	103.4	(75.1-138.8)
<u>Lung and Bronchus</u>									
Male	9	6.7	133.9	(61.1-254.2)					
Female	9	6.0	151.2	(69.0-287.0)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Brookline

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	51	53.3	95.7	(71.3-125.9)	Male	40	29.6	135.1	(96.5-184.0)
Female	26	22.2	116.9	(76.3-171.2)	Female	38	28.9	131.5	(93.0-180.5)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	13	10.5	123.9	(65.9-212.0)	Male	6	7.8	77.2	(28.2-168.0)
Female	11	10.5	105.2	(52.4-188.3)	Female	8	7.2	110.5	(47.6-217.8)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	3	1.7	nc	(nc-nc)	Male	40	28.3	141.5	(101.1-192.7)
Female	259	230.0	112.6	(99.3-127.2)	Female	35	29.4	119.0	(82.9-165.5)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	9	10.9	82.4	(37.6-156.5)	Male	16	20.4	78.4	(44.8-127.3)
<u>Colon / Rectum</u>					Female	14	11.7	119.2	(65.1-200.0)
Male	69	81.1	85.1	(66.2-107.7)	<u>Ovary</u>				
Female	84	93.9	89.5	(71.4-110.8)	Female	29	24.8	117.0	(78.3-168.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	9	13.2	68.0	(31.0-129.1)	Male	13	15.3	85.1	(45.2-145.5)
Female	2	4.5	nc	(nc-nc)	Female	22	19.6	112.4	(70.4-170.2)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	6	5.2	115.2	(42.1-250.8)	Male	229	212.6	107.7	(94.2-122.6)
Female	8	5.3	149.7	(64.5-295.0)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	9	13.8	65.3	(29.8-123.9)
Male	32	22.0	145.7	(99.6-205.7)	Female	12	10.2	117.6	(60.7-205.4)
Female	18	16.0	112.4	(66.6-177.6)	<u>Testis</u>				
<u>Larynx</u>					Male	14	10.0	139.9	(76.4-234.7)
Male	6	9.2	65.0	(23.7-141.4)	<u>Thyroid</u>				
Female	2	2.8	nc	(nc-nc)	Male	15	6.3	239.9	(134.2-395.7)
<u>Leukemia</u>					Female	41	24.5	167.3	(120.1-227.0)
Male	21	17.0	123.5	(76.4-188.8)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	17	16.6	102.7	(59.8-164.4)	Female	65	46.3	140.5	(108.4-179.0)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	8	10.2	78.2	(33.7-154.1)	Male	707	716.2	98.7	(91.6-106.3)
Female	5	4.6	108.6	(35.0-253.5)	Female	839	781.8	107.3	(100.2-114.8)
<u>Lung and Bronchus</u>									
Male	59	100.1	59.0	(44.9-76.1)					
Female	84	102.3	82.1	(65.5-101.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Buckland

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	1	2.3	nc	(nc-nc)	Male	0	1.2	nc	(nc-nc)
Female	0	0.7	nc	(nc-nc)	Female	1	0.9	nc	(nc-nc)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	0	0.4	nc	(nc-nc)	Male	0	0.3	nc	(nc-nc)
Female	0	0.4	nc	(nc-nc)	Female	1	0.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.1	nc	(nc-nc)	Male	2	1.2	nc	(nc-nc)
Female	9	8.4	107.6	(49.1-204.3)	Female	0	1.0	nc	(nc-nc)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	0	0.4	nc	(nc-nc)	Male	1	0.9	nc	(nc-nc)
<u>Colon / Rectum</u>					Female	1	0.4	nc	(nc-nc)
Male	2	3.5	nc	(nc-nc)	<u>Ovary</u>				
Female	4	3.0	nc	(nc-nc)	Female	0	0.9	nc	(nc-nc)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	1	0.6	nc	(nc-nc)	Male	0	0.7	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	Female	0	0.6	nc	(nc-nc)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	0	0.2	nc	(nc-nc)	Male	3	9.3	nc	(nc-nc)
Female	0	0.1	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	0	0.6	nc	(nc-nc)
Male	0	1.0	nc	(nc-nc)	Female	0	0.3	nc	(nc-nc)
Female	0	0.6	nc	(nc-nc)	<u>Testis</u>				
<u>Larynx</u>					Male	0	0.3	nc	(nc-nc)
Male	2	0.4	nc	(nc-nc)	<u>Thyroid</u>				
Female	0	0.1	nc	(nc-nc)	Male	0	0.2	nc	(nc-nc)
<u>Leukemia</u>					Female	0	0.8	nc	(nc-nc)
Male	1	0.7	nc	(nc-nc)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	1	0.5	nc	(nc-nc)	Female	2	1.7	nc	(nc-nc)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	0	0.4	nc	(nc-nc)	Male	20	30.8	65.0	(39.7-100.3)
Female	0	0.2	nc	(nc-nc)	Female	28	26.9	104.1	(69.1-150.4)
<u>Lung and Bronchus</u>									
Male	2	4.4	nc	(nc-nc)					
Female	5	3.6	139.5	(45.0-325.7)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;



# Burlington

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<b><u>Bladder, Urinary</u></b>					<b><u>Melanoma of Skin</u></b>				
Male	29	24.9	116.5	(78.0-167.3)	Male	22	13.9	158.7	(99.4-240.3)
Female	4	8.7	nc	(nc-nc)	Female	11	11.2	98.5	(49.1-176.3)
<b><u>Brain and Other Nervous System</u></b>					<b><u>Multiple Myeloma</u></b>				
Male	6	4.9	121.7	(44.4-264.9)	Male	1	3.7	nc	(nc-nc)
Female	3	4.2	nc	(nc-nc)	Female	2	2.8	nc	(nc-nc)
<b><u>Breast</u></b>					<b><u>Non-Hodgkin Lymphoma</u></b>				
Male	0	0.8	nc	(nc-nc)	Male	14	13.0	107.4	(58.7-180.2)
Female	102	96.9	105.3	(85.8-127.8)	Female	12	11.4	105.0	(54.2-183.4)
<b><u>Cervix Uteri</u></b>					<b><u>Oral Cavity &amp; Pharynx</u></b>				
Female	5	4.3	116.3	(37.5-271.4)	Male	9	10.1	88.9	(40.6-168.7)
<b><u>Colon / Rectum</u></b>					Female	5	4.7	105.5	(34.0-246.1)
Male	27	38.1	70.9	(46.7-103.2)	<b><u>Ovary</u></b>				
Female	34	33.9	100.4	(69.5-140.3)	Female	3	10.1	nc	(nc-nc)
<b><u>Esophagus</u></b>					<b><u>Pancreas</u></b>				
Male	8	6.6	122.0	(52.5-240.3)	Male	3	7.2	nc	(nc-nc)
Female	5	1.7	296.5	(95.5-691.9)	Female	11	7.2	151.8	(75.7-271.7)
<b><u>Hodgkin Lymphoma</u></b>					<b><u>Prostate</u></b>				
Male	3	2.1	nc	(nc-nc)	Male	120	112.3	106.8	(88.6-127.7)
Female	2	1.7	nc	(nc-nc)	<b><u>Stomach</u></b>				
<b><u>Kidney &amp; Renal Pelvis</u></b>					Male	9	6.3	142.3	(64.9-270.1)
Male	9	11.0	81.9	(37.4-155.5)	Female	3	3.4	nc	(nc-nc)
Female	5	6.7	74.6	(24.1-174.2)	<b><u>Testis</u></b>				
<b><u>Larynx</u></b>					Male	3	3.7	nc	(nc-nc)
Male	7	4.7	149.5	(59.9-308.0)	<b><u>Thyroid</u></b>				
Female	0	1.3	nc	(nc-nc)	Male	2	2.9	nc	(nc-nc)
<b><u>Leukemia</u></b>					Female	15	9.1	164.7	(92.1-271.6)
Male	8	7.9	101.4	(43.7-199.8)	<b><u>Uteri Corpus and Uterus, NOS</u></b>				
Female	10	6.2	161.9	(77.5-297.8)	Female	21	20.5	102.7	(63.5-157.0)
<b><u>Liver and Intrahepatic Bile Ducts</u></b>					<b><u>All Sites / Types</u></b>				
Male	4	5.1	nc	(nc-nc)	Male	345	351.0	98.3	(88.2-109.2)
Female	0	1.7	nc	(nc-nc)	Female	313	313.0	100.0	(89.2-111.7)
<b><u>Lung and Bronchus</u></b>									
Male	37	49.7	74.4	(52.4-102.6)					
Female	44	43.7	100.7	(73.1-135.1)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Cambridge

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	58	72.1	80.4	(61.1-103.9)	Male	43	44.0	97.7	(70.7-131.6)
Female	27	28.8	93.8	(61.8-136.5)	Female	32	42.3	75.7	(51.7-106.8)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	8	16.6	48.2	(20.8-95.0)	Male	10	10.6	94.1	(45.0-173.0)
Female	11	15.1	72.9	(36.4-130.5)	Female	10	9.4	106.2	(50.9-195.4)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	2	2.3	nc	(nc-nc)	Male	27	41.9	64.5	(42.5-93.8)
Female	295	317.6	92.9	(82.6-104.1)	Female	37	39.9	92.8	(65.3-127.9)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	10	16.4	61.1	(29.3-112.4)	Male	30	28.9	103.6	(69.9-148.0)
<u>Colon / Rectum</u>					Female	13	16.0	81.1	(43.2-138.8)
Male	97	110.7	87.6	(71.0-106.9)	<u>Ovary</u>				
Female	85	118.9	71.5	(57.1-88.4)	Female	38	34.2	111.3	(78.7-152.7)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	10	18.2	55.1	(26.4-101.3)	Male	21	20.7	101.2	(62.6-154.7)
Female	7	5.7	123.0	(49.3-253.5)	Female	27	24.9	108.6	(71.5-158.0)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	9	10.6	84.8	(38.7-161.0)	Male	311	291.0	106.9	(95.3-119.4)
Female	4	9.3	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	18	18.8	95.8	(56.7-151.4)
Male	26	31.0	84.0	(54.8-123.0)	Female	17	12.7	134.3	(78.2-215.0)
Female	19	21.8	87.0	(52.4-135.9)	<u>Testis</u>				
<u>Larynx</u>					Male	17	21.3	79.8	(46.5-127.8)
Male	13	12.7	102.0	(54.3-174.4)	<u>Thyroid</u>				
Female	3	3.9	nc	(nc-nc)	Male	15	10.5	143.4	(80.2-236.5)
<u>Leukemia</u>					Female	33	38.6	85.4	(58.8-120.0)
Male	24	25.2	95.3	(61.0-141.7)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	21	22.2	94.4	(58.4-144.3)	Female	73	63.9	114.3	(89.6-143.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	14	14.4	97.0	(53.0-162.8)	Male	921	1008.4	91.3	(85.5-97.4)
Female	9	6.0	150.2	(68.6-285.2)	Female	956	1062.5	90.0	(84.4-95.9)
<u>Lung and Bronchus</u>									
Male	110	137.4	80.0	(65.8-96.5)					
Female	115	137.6	83.6	(69.0-100.3)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;

# Canton

Observed and Expected Case Counts, with Standardized Incidence Ratios, 1999-2003

	<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>		<u>Obs</u>	<u>Exp</u>	<u>SIR</u>	<u>95% CI</u>
<u>Bladder, Urinary</u>					<u>Melanoma of Skin</u>				
Male	22	24.9	88.3	(55.3-133.7)	Male	14	12.9	108.4	(59.2-181.8)
Female	11	9.8	112.2	(55.9-200.7)	Female	7	10.9	64.0	(25.7-131.9)
<u>Brain and Other Nervous System</u>					<u>Multiple Myeloma</u>				
Male	4	4.5	nc	(nc-nc)	Male	4	3.6	nc	(nc-nc)
Female	4	4.2	nc	(nc-nc)	Female	1	3.2	nc	(nc-nc)
<u>Breast</u>					<u>Non-Hodgkin Lymphoma</u>				
Male	0	0.8	nc	(nc-nc)	Male	13	12.4	104.5	(55.6-178.8)
Female	94	95.4	98.5	(79.6-120.5)	Female	12	12.4	96.5	(49.8-168.6)
<u>Cervix Uteri</u>					<u>Oral Cavity &amp; Pharynx</u>				
Female	2	4.1	nc	(nc-nc)	Male	5	9.1	54.8	(17.7-128.0)
<u>Colon / Rectum</u>					Female	3	4.9	nc	(nc-nc)
Male	44	37.5	117.3	(85.2-157.5)	<u>Ovary</u>				
Female	49	41.1	119.3	(88.3-157.7)	Female	7	10.2	68.4	(27.4-141.0)
<u>Esophagus</u>					<u>Pancreas</u>				
Male	7	6.1	114.7	(46.0-236.4)	Male	13	7.1	183.6	(97.7-314.0)
Female	6	2.0	307.1	(112.1-668.4)	Female	12	8.7	138.7	(71.6-242.3)
<u>Hodgkin Lymphoma</u>					<u>Prostate</u>				
Male	5	1.8	279.6	(90.1-652.6)	Male	110	98.8	111.3	(91.5-134.2)
Female	2	1.6	nc	(nc-nc)	<u>Stomach</u>				
<u>Kidney &amp; Renal Pelvis</u>					Male	4	6.3	nc	(nc-nc)
Male	17	10.0	169.7	(98.8-271.7)	Female	4	4.4	nc	(nc-nc)
Female	8	6.9	116.0	(50.0-228.6)	<u>Testis</u>				
<u>Larynx</u>					Male	1	3.1	nc	(nc-nc)
Male	2	4.2	nc	(nc-nc)	<u>Thyroid</u>				
Female	2	1.2	nc	(nc-nc)	Male	3	2.5	nc	(nc-nc)
<u>Leukemia</u>					Female	17	8.3	204.8	(119.2-328.0)
Male	9	7.6	118.3	(54.0-224.6)	<u>Uteri Corpus and Uterus, NOS</u>				
Female	8	7.0	114.2	(49.2-225.0)	Female	18	19.3	93.4	(55.3-147.7)
<u>Liver and Intrahepatic Bile Ducts</u>					<u>All Sites / Types</u>				
Male	4	4.7	nc	(nc-nc)	Male	334	326.8	102.2	(91.5-113.8)
Female	4	2.0	nc	(nc-nc)	Female	345	328.1	105.1	(94.3-116.8)
<u>Lung and Bronchus</u>									
Male	41	46.8	87.7	(62.9-118.9)					
Female	49	45.2	108.4	(80.2-143.4)					

- Obs = observed case count; Exp = expected case count;
- SIR = standardized incidence ratio ( (Obs / Exp) X 100);
- 95% CI = 95% confidence intervals, a measure of the statistical significance of the SIR;
- Shading indicates the statistical significance of the SIR at 95% level of probability;
- nc = The SIR and 95% CI were not calculated when Obs < 5;